As shown in Figure 1B (P < 0.05), DLBCL patients who achieved clinical efficacy (including CR and partial remission) exhibited lower CISD2 levels than those with clinical inefficacy (including progressive disease and stable disease). This evidence concerns the gene CISD2 and diffuse large B-cell lymphoma.